10-Q: Avidity Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Avidity Biosciences reported a net loss of $68.9 million for the first quarter of 2024, while highlighting progress in clinical development and a strong cash position.

Summary

• Avidity Biosciences reported a net loss of $68.9 million for the first quarter of 2024, compared to a net loss of $52.4 million for the same period in 2023.
• The company's collaboration revenue increased to $3.5 million from $2.2 million year-over-year, primarily due to the BMS agreement.
• Research and development expenses rose to $66.8 million, up from $47.8 million in the prior year, driven by increased clinical trial and manufacturing costs.
• General and administrative expenses also increased to $13.9 million from $12.1 million year-over-year.
• The company's cash, cash equivalents, and marketable securities totaled $915.9 million as of March 31, 2024.
• Avidity believes its current financial resources will fund operations for at least 12 months from the filing date of this report.
• The company completed a private placement in March 2024, raising $379.8 million in net proceeds.
• The company is on track to initiate the global Phase 3 HARBOR trial of del-desiran this quarter.
• The company plans to share preliminary data from the Phase 1/2 FORTITUDE trial of AOC 1020 in FSHD in the second quarter of 2024.
• The company plans to share 5 mg/kg cohort data from the Phase 1/2 EXPLORE44 trial of AOC 1044 in people living with DMD44 in the second half of 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has a strong cash position and is progressing its clinical programs, the increased net loss and R&D expenses are concerning. The successful capital raise and positive clinical data provide some optimism, but the overall sentiment is cautiously optimistic.

Positives

• The company has a strong cash position of $915.9 million, which is expected to fund operations for at least 12 months.
• The company successfully raised $379.8 million through a private placement.
• Collaboration revenue increased due to the BMS agreement.
• The company is progressing its clinical programs with multiple data readouts expected in 2024.
• Del-desiran has shown positive long-term safety and tolerability data.
• The company is on track to initiate the global Phase 3 HARBOR trial of del-desiran this quarter.

Negatives

• The company reported a net loss of $68.9 million for the first quarter of 2024, which is an increase from the $52.4 million loss in the same period of 2023.
• Research and development expenses increased significantly to $66.8 million, driven by higher manufacturing costs.
• General and administrative expenses also increased to $13.9 million.

Risks

• The company has incurred operating losses since inception and expects to continue to incur net losses.
• The company's future success depends on the successful development and commercialization of its product candidates, which is subject to significant risks and uncertainties.
• The company may need to raise additional capital in the future, and there is no guarantee that it will be able to do so on favorable terms or at all.
• The company's development programs are subject to regulatory risks, including the possibility of delays or denials of approvals.
• The company is subject to a material weakness in internal control over financial reporting related to segregation of duties over certain information technology general controls.

Future Outlook

The company expects to continue to incur net losses and will need to raise additional capital through equity offerings, debt financings, or other capital sources. The company plans to report data from multiple ongoing trials in 2024 and initiate its global Phase 3 HARBOR trial of del-desiran for DM1 in the second quarter of 2024.

Management Comments

• The company believes that existing cash, cash equivalents and marketable securities will be sufficient to fund the company's operations for at least 12 months from the date of the filing of this Form 10-Q.
• The company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other arrangements.

Industry Context

The company's focus on RNA therapeutics and Antibody Oligonucleotide Conjugates (AOCs) positions it within a growing field of precision medicine. The collaborations with BMS and Eli Lilly highlight the industry's interest in novel therapeutic platforms for addressing previously untreatable diseases. The company's progress in clinical trials and the receipt of orphan and fast track designations are consistent with the industry's focus on developing treatments for rare diseases.

Comparison to Industry Standards

• Avidity's cash burn rate of approximately $70 million per quarter is typical for a clinical-stage biotech company with multiple ongoing trials.
• The company's collaboration revenue of $3.5 million is relatively low compared to companies with approved products or more advanced partnerships, but is expected to increase as programs progress.
• The company's R&D expenses of $66.8 million are in line with other companies in the clinical stage of development, particularly those with multiple programs in Phase 1/2 trials.
• The company's cash position of $915.9 million is strong compared to many peers, providing a runway for continued development.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are also focused on RNA therapeutics, have similar R&D spending and collaboration strategies, but have more advanced pipelines and commercial products.
• The company's private placement of $379.8 million is a significant capital raise, comparable to other biotech companies seeking to fund late-stage clinical trials and commercialization efforts.

Corporate Governance

Related Party Transactions

• One of the investors in the private placement was a principal owner of more than 10% of the voting interest in the Company, purchasing 2,121,213 shares for $35.0 million.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's growth and financial stability will affect employee job security and compensation.
• Patients: The company's clinical trials and potential product approvals will impact patients with the targeted diseases.
• Collaborators: The company's partnerships with BMS and Eli Lilly will impact the development and commercialization of their respective programs.
• Creditors: The company's financial health will impact its ability to meet its obligations.

Next Steps

• Initiate the global Phase 3 HARBOR trial of del-desiran for DM1 in the second quarter of 2024.
• Share preliminary data from the Phase 1/2 FORTITUDE trial of AOC 1020 in FSHD in the second quarter of 2024.
• Share 5 mg/kg cohort data from the Phase 1/2 EXPLORE44 trial of AOC 1044 in people living with DMD44 in the second half of 2024.

Key Dates

Keywords

RNA therapeutics, Antibody Oligonucleotide Conjugates, AOC, clinical trials, biopharmaceutical, del-desiran, myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, private placement, research collaboration, BMS, Eli Lilly